407 related articles for article (PubMed ID: 28336670)
1. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
Toska E; Osmanbeyoglu HU; Castel P; Chan C; Hendrickson RC; Elkabets M; Dickler MN; Scaltriti M; Leslie CS; Armstrong SA; Baselga J
Science; 2017 Mar; 355(6331):1324-1330. PubMed ID: 28336670
[TBL] [Abstract][Full Text] [Related]
2. Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
Blawski R; Vokshi BH; Guo X; Kittane S; Sallaku M; Chen W; Gjyzari M; Cheung T; Zhang Y; Simpkins C; Zhou W; Kulick A; Zhao P; Wei M; Shivashankar P; Prioleau T; Razavi P; Koche R; Rebecca VW; de Stanchina E; Castel P; Chan HM; Scaltriti M; Cocco E; Ji H; Luo M; Toska E
Cell Rep; 2024 May; 43(5):114174. PubMed ID: 38700982
[TBL] [Abstract][Full Text] [Related]
3. PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression.
Toska E; Castel P; Chhangawala S; Arruabarrena-Aristorena A; Chan C; Hristidis VC; Cocco E; Sallaku M; Xu G; Park J; Minuesa G; Shifman SG; Socci ND; Koche R; Leslie CS; Scaltriti M; Baselga J
Cell Rep; 2019 Apr; 27(1):294-306.e5. PubMed ID: 30943409
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kα inhibition through the transcriptional regulation of ERα.
Ding J; Wang X; Zhang Y; Sang X; Yi J; Liu C; Liu Z; Wang M; Zhang N; Xue Y; Shen L; Zhao W; Luo F; Liu P; Cheng H
Cancer Lett; 2019 Jan; 440-441():54-63. PubMed ID: 30315845
[TBL] [Abstract][Full Text] [Related]
5. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer.
Macaluso M; Cinti C; Russo G; Russo A; Giordano A
Oncogene; 2003 Jun; 22(23):3511-7. PubMed ID: 12789259
[TBL] [Abstract][Full Text] [Related]
6. PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.
Magnani L; Ballantyne EB; Zhang X; Lupien M
PLoS Genet; 2011 Nov; 7(11):e1002368. PubMed ID: 22125492
[TBL] [Abstract][Full Text] [Related]
7. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
Xu G; Chhangawala S; Cocco E; Razavi P; Cai Y; Otto JE; Ferrando L; Selenica P; Ladewig E; Chan C; Da Cruz Paula A; Witkin M; Cheng Y; Park J; Serna-Tamayo C; Zhao H; Wu F; Sallaku M; Qu X; Zhao A; Collings CK; D'Avino AR; Jhaveri K; Koche R; Levine RL; Reis-Filho JS; Kadoch C; Scaltriti M; Leslie CS; Baselga J; Toska E
Nat Genet; 2020 Feb; 52(2):198-207. PubMed ID: 31932695
[TBL] [Abstract][Full Text] [Related]
8. Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor-positive Breast Cancer.
Jones RB; Farhi J; Adams M; Parwani KK; Cooper GW; Zecevic M; Lee RS; Hong AL; Spangle JM
Cancer Res Commun; 2022 Dec; 2(12):1569-1578. PubMed ID: 36970726
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic PIK3CA mutations increase dependency on the mRNA cap methyltransferase, RNMT, in breast cancer cells.
Dunn S; Lombardi O; Lukoszek R; Cowling VH
Open Biol; 2019 Apr; 9(4):190052. PubMed ID: 30991934
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER
Ros S; Wright AJ; D'Santos P; Hu DE; Hesketh RL; Lubling Y; Georgopoulou D; Lerda G; Couturier DL; Razavi P; Pelossof R; Batra AS; Mannion E; Lewis DY; Martin A; Baird RD; Oliveira M; de Boo LW; Linn SC; Scaltriti M; Rueda OM; Bruna A; Caldas C; Brindle KM
Cancer Cell; 2020 Oct; 38(4):516-533.e9. PubMed ID: 32976773
[TBL] [Abstract][Full Text] [Related]
11. Genomic Alterations in
Cai Y; Xu G; Wu F; Michelini F; Chan C; Qu X; Selenica P; Ladewig E; Castel P; Cheng Y; Zhao A; Jhaveri K; Toska E; Jimenez M; Jacquet A; Tran-Dien A; Andre F; Chandarlapaty S; Reis-Filho JS; Razavi P; Scaltriti M
Cancer Res; 2021 May; 81(9):2470-2480. PubMed ID: 33685991
[TBL] [Abstract][Full Text] [Related]
12. More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response.
Fu X; Huang C; Schiff R
Breast Cancer Res; 2011 Apr; 13(2):307. PubMed ID: 21575280
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
14. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.
Wang C; Mayer JA; Mazumdar A; Brown PH
Breast Cancer Res Treat; 2012 Jun; 133(2):487-500. PubMed ID: 21947652
[TBL] [Abstract][Full Text] [Related]
15. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
Shariati M; Evans KW; Zheng X; Bristow CA; Ng PK; Rizvi YQ; Tapia C; Yang F; Carugo A; Heffernan TP; Peoples MD; Tripathy D; Meric-Bernstam F
Oncogene; 2021 Jul; 40(26):4425-4439. PubMed ID: 34108622
[TBL] [Abstract][Full Text] [Related]
17. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
19. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
Jing X; Liang H; Hao C; Hongxia L; Cui X
Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
[TBL] [Abstract][Full Text] [Related]
20. Identification of lineage-specific epigenetic regulators FOXA1 and GRHL2 through chromatin accessibility profiling in breast cancer cell lines.
Yang L; Kumegawa K; Saeki S; Nakadai T; Maruyama R
Cancer Gene Ther; 2024 May; 31(5):736-745. PubMed ID: 38429368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
